ZYME · Zymeworks Inc. · Webcasts, Transcripts & Audio
$25.15
-0.81 (-3.12%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.86B
Shares
70.96M
Volume · Oct 2
844.47K
Avg daily vol (3M)
655.01K
Zymeworks Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Zymeworks Inc. (ZYME), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼40.1%
$2.63M
−$47.85M
'22 Q3
22-11-08
·
$402.49M
$309.43M
'22 Q4
23-03-07
▲1756.9%
$35.58M
−$24.35M
'23 Q1
23-05-08
▲28.7%
$7.00M
−$51.15M
'23 Q2
23-08-10
▲527.4%
$16.51M
−$28.69M
'23 Q3
23-11-07
▼95.8%
$16.93M
−$14.48M
'23 Q4
24-03-06
▼71.8%
$10.03M
−$31.65M
'24 Q1
24-05-02
▲174.8%
$19.24M
−$37.69M
'24 Q2
24-08-01
▼3.1%
$16.00M
−$29.85M
'24 Q3
24-10-31
▲83.3%
$31.03M
−$23.51M
'24 Q4
25-01-08
▲170.3%
$27.11M
−$22.64M
'25 Q1
25-05-08
▲153.2%
$48.73M
$2.32M
'25 Q2
25-08-07
▲72.6%
$27.61M
−$19.60M
'25 Q3
25-11-06
▼91.9%
$2.52M
−$41.21M
'25 Q4
26-03-02
▼91.1%
$2.41M
−$44.16M
'26 Q1
26-05-07
LATEST
▼90.6%
$4.59M
−$45.02M
'26 Q2
26-09-28
Conference
Investor event
2026-09-28
Zymeworks Inc. (ZYME) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-09-28
Zymeworks Inc. (ZYME) Q2 2026 Earnings Call
Revenue
$4.59M
▼ 90.6% YoY Diluted EPS
$-0.62
▼ 2166.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Zymeworks Inc. (ZYME) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Zymeworks Inc. (ZYME) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Confident tone
ADC pipeline and AACR data
Zanidatamab regulatory milestones
Royalty aggregation business model
Revenue
$2.41M
▼ 91.1% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-21
Zymeworks Inc. (ZYME) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-02
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Confident tone
Zanidatumab GEA regulatory and commercial progress
Royalty and milestone economics from collaborations
ZW191 Phase I progress in GPC3-expressing tumors
Revenue
$2.52M*
▼ 91.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Confident tone
ZW191 Phase I ADC (folate receptor alpha)
ZW251 Phase I ADC (GPC3, hepatocellular carcinoma)
DLL3 T-cell engager (preclinical/ZW171)
Revenue
$27.61M
▲ 72.6% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
Confident tone
Wholly-owned ADC pipeline (ZW171, ZW191, ZW251, ZW220)
Timing and disclosure of ZW191 data
Preclinical IL-4/IL-33 bispecific (ZW1528) for COPD
Revenue
$48.73M
▲ 153.2% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
Positive tone
Bispecific T-cell engager vs ADC strategy
Pipeline and preclinical data
Partnerships and milestones
Revenue
$27.11M
▲ 170.3% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-08
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Positive tone
Partnership milestones and revenue
ADC programs (ZW251, ZW220, ZW191)
Financial performance and operating expenses
Revenue
$31.03M*
▲ 83.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Positive tone
Wholly owned pipeline progress (ZW171, ZW191, ZW220, ZW251)
Zanidatamab (Zani) updates with Jazz Pharmaceuticals
Partner programs and licensing revenue
Revenue
$16.00M
▼ 3.1% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Positive tone
Wholly-owned pipeline advancement
Zanidatamab regulatory progress
Mesothelin T-cell engager safety and design (ZW171)
Revenue
$19.24M
▲ 174.8% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
Confident tone
Upcoming INDs and Phase 1 Studies
Zanidatamab Partnership Progress
TriTCE Trispecific Platform
Revenue
$10.03M
▼ 71.8% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
Confident tone
5x5 early-stage pipeline
Zanidatamab commercial outlook
Partner execution (Jazz/BeiGene)
Revenue
$16.93M*
▼ 95.8% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 527.4% YoY Diluted EPS
$-0.41
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript
Revenue
$7.00M
▲ 28.7% YoY Diluted EPS
$-0.76
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript
Revenue
$35.58M
▲ 1756.9% YoY Diluted EPS
$-0.37
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Zymeworks Inc. (ZYME) Q4 2022 Earnings Call Transcript
Revenue
$402.49M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Zymeworks Inc. (ZYME) Q3 2022 Earnings Call Transcript
Revenue
$2.63M
▼ 40.1% YoY Diluted EPS
$-0.72
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Zymeworks Inc. (ZYME) Q2 2022 Earnings Call Transcript
Revenue
$5.44M
Diluted EPS
$-0.97
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Zymeworks Inc. (ZYME) Q1 2022 Earnings Call Transcript
Revenue
$1.92M
Diluted EPS
$-1.19
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Zymeworks Inc. (ZYME) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–23 of 23 webcasts
Key facts
CIK
1937653
CUSIP
98985Y108
13F (30d)
10 filings
6 filers
Visit website
Investor relations